TY - JOUR T1 - COVID-19 genomic susceptibility: Definition of <em>ACE2</em> variants relevant to human infection with SARS-CoV-2 in the context of ACMG/AMP Guidance JF - medRxiv DO - 10.1101/2020.05.12.20098160 SP - 2020.05.12.20098160 AU - Claire L Shovlin AU - Marcela P. Vizcaychipi Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/04/2020.05.12.20098160.abstract N2 - Background Mortality remains very high and unpredictable in CoViD-19, with intense public protection strategies tailored to preceived risk. Males are at greater risk of severe CoViD-19 complications. Genomic studies are in process to identify differences in host susceptibility to SARS-CoV-2 infection.Methods Genomic structures were examined for the ACE2 gene that encodes angiotensin-converting enzyme 2, the obligate receptor for SARS-CoV-2. Variants in 213,158 exomes/genomes were integrated with ACE2 protein functional domains, and pathogenicity criteria from the American Society of Human Genetics and Genomics/Association for Molecular Pathology.Results 483 variants were identified in the 19 exons of ACE2 on the X chromosome. All variants were rare, including nine loss-of-function (potentially SARS-CoV-2 protective) alleles present only in female heterozygotes. Unopposed variant alleles were more common in males (262/3596 [7.3%] nucleotides) than females (9/3596 [0.25%] nucleotides, p&lt;0.0001). 37 missense variants substituted amino acids in SARS-CoV-2 interacting regions or critical domains for transmembrane ACE2 expression. Four upstream open reading frames with 31 associated variants were identified. Excepting loss-of-function alleles, variants would not meet minimum criteria for classification as ‘Likely Pathogenic/beneficial’ if differential frequencies emerged in patients with CoViD-19.Conclusions Males are more exposed to consequences from a single variant ACE2 allele. Common risk/beneficial alleles are unlikely in regions subject to evolutionary constraint. ACE2 upstream open reading frames may have implications for aminoglycoside use in SARS-CoV-2-infected patients. For this SARS-CoV-2-interacting protein with pre-identified functional domains, pre-emptive functional and computational studies are encouraged to accelerate interpretations of genomic variation for personalised and public health use.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work received no specific funding. CLS also acknowledges infrastructure support provided by the NIHR Imperial Biomedical Research CentreAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approvals were not required as all data reported were already anonymised and in the public domain.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available in the primary data sources (references 15-19,21). We are in the process of developing an accessible database that will be open access following peer review publication. ER -